NSAIDs' CV Risk in Arthritis


Compared to Naproxen, Diclofenac use increased myocardial infarction risk in Ankylosing Spondylitis patients, but not in Osteoarthritis patients.  Perhaps Diclofenac’s risk is made evident by an already inflammatory condition like AS.

The use of celecoxib in patients with OA and RA was associated with a similar or a lower risk for cardiovascular, gastrointestinal, and renal adverse events…

Differences in Safety of Nonsteroidal Antiinflammatory Drugs in Patients With Osteoarthritis and Patients With Rheumatoid Arthritis: A Randomized Clinical Trial


“Treatment with celecoxib at approved dosages conferred a similar or lower risk of CV, GI, and renal adverse events compared with treatment with ibuprofen or naproxen in patients with OA and patients with RA.”

Among the non-selective COX-inhibitors, Ibuprofen and Naproxen are known to be relatively safer with regards to major adverse cardiovascular events.  The relative safety of Celecoxib over Ibuprofen and Naproxen across the 3 outcomes (heart, gut, kidney) were more significant in OA than in RA patients, again possibly reflecting the higher inflammatory burden and baseline risks RA patients are already subjected to from their disease.

The PRECISION trial reported last year that celecoxib appears to be safer than the NSAIDs naproxen or ibuprofen in treating osteoarthritis (OA) and rheumatoid…

Adding Aspirin appears to negate any  cardiovascular or renal benefit Celecoxib may confer over the use of Ibuprofen or Naproxen.

Should celecoxib (Celebrex) be officially declared as no riskier for the heart than other non-steroidal anti-inflammatory drugs (NSAIDs) naproxen and ibuprofen, and…